New painkiller may prevent sudden severe pain after shoulder surgery
NCT ID NCT07196631
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tested whether a long-acting form of the painkiller bupivacaine (liposomal bupivacaine) could prevent the sudden, severe pain that often occurs after a shoulder nerve block wears off. 100 adults having shoulder arthroscopy were randomly assigned to receive either liposomal bupivacaine or the standard drug ropivacaine. The main goal was to see if liposomal bupivacaine reduced the chance of this 'rebound pain' in the first 24 hours after surgery.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- liposomal bupivacaine
- What this could lead to
- If it works, this could provide a longer-lasting pain block after shoulder surgery, reducing the sudden severe pain that often occurs when the initial anesthetic wears off.
- What could go wrong
- This is a small, completed phase 4 trial with only 100 participants. Previous studies have shown mixed results, so the benefit may be modest or not clinically significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
100 people
The number who actually took part.
- Started
-
Sep 2025
- Finished
-
Jan 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * adults between 18 and 65 year-old * American Society of Anesthesiologist (ASA) grades 1 to 3 physical classification status * patients unilateral primary arthroscopic shoulder surgery lasting 1to 4 hours Exclusion Criteria: * had an allergy or intolerance to amide-type local anesthetics * objective evidence of nerve damage in the affected upper limb * local infection * impaired renal function (defined as effective glomerular filtration rate \< 30ml/min/1.73m2) * coagulation disorders * respiratory compromise（requires long term oxygen） * had participated in another research trial involving an investigational medicinal product in the 6 months before randomization
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Liposomal bupivacaine are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Anesthesiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430030, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a weaker nerve block mean less pain after shoulder surgery?
- A new battle plan against Post-Surgery pain rebound
- Can a 48-Hour nerve block prevent the 'Rebound Pain' after shoulder surgery?
- Could a simple steroid injection replace a catheter for shoulder surgery pain?
- New study tests simple trick to stop pain after nerve blocks wear off
- New study tests simple trick to stop pain after nerve block wears off